ABR-238901
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4) . ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3].
Product Specifications
CAS Number
1638200-22-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/abr-238901.html
Purity
98.92
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(NC1=C(O)C(Cl)=CN=C1)(C2=CN=C(C(Br)=C2)OC)=O
Molecular Formula
C11H9BrClN3O4S
Molecular Weight
394.63
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FAM100A (Family with Sequence Similarity 100, Member A, FLJ31223, FLJ32185, PP11303) (MaxLight 405) discontinued
